Treatment of neutropenic patients with fever who are suspected to have a gram positive infection (a specific kind of bacteria) - Article
Clinical Trial: Treatment of neutropenic patients with fever who are suspected to have a gram positive infection (a specific kind of bacteria)
This study has been completed.
|Condition||Treatment or Intervention||Phase|
Gram-Positive Bacterial Infections
| Drug: Antibiotic |
|Phase III |
MedlinePlus related topics: Bacterial Infections; Blood and Blood Disorders; Cancer; Cancer Alternative Therapy; Fever
Study Type: Interventional
Study Design: Treatment
Ages Eligible for Study: 13 Years and above, Genders Eligible for Study: Both
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
- Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).
- Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.
- Patients with fever due to known causes.
- Patients with HIV.
- Patients with recent bone marrow transplant.
- Patients with an infected indwelling catheter that cannot be removed.
- Patients who have received more than one day of another antibiotic before entering the trial.
- Patients with endocarditis, osteomyelitis, meningitis, CNS infections.
Research Center, San Diego, California, 92134, United States
Research Center, Los Angeles, California, 90033, United States
Research Center, Orange, California, 92868, United States
Research Center, Miami, Florida, 33136, United States
Research Center, Springfield, Illinois, 62701, United States
Research Center, Maywood, Illinois, 60153, United States
Research Center, Lexington, Kentucky, 40536, United States
Research Center, Worcester, Massachusetts, 01655, United States
Research Center, Kalamazoo, Michigan, 49001, United States
Research Center, Perth Amboy, New Jersey, 08861, United States
Research Center, Bronx, New York, 10467-2490, United States
Research Center, Youngstown, Ohio, 44501, United States
Research Center, Jackson, Tennessee, 38301, United States
Research Center, Houston, Texas, 77030-4211, United States
Research Center, Houston, Texas, 77030, United States
Research Center, Richmond, Virginia, 23249, United States
Research Center, Falls Church, Virginia, 22042, United States
Research Center, Richmond, Virginia, 23294, United States
Research Center, Tacoma, Washington, 98405, United States
Research Center, Milwaukee, Wisconsin, 53226, United States
Research Center, Hato Rey, 00985, Puerto Rico
Record last reviewed: March 2004
Last Updated: October 13, 2004
Record first received: May 3, 2002
ClinicalTrials.gov Identifier: NCT00035425
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005
- Vancomycin-Intermediate/Resistant Staphylococcus aureus(VISA/VRSA) Infections (Centers for Disease Control and Prevention)